Skye Bioscience, Inc. (SKYE)
1.05
+0.01
(+0.96%)
USD |
NASDAQ |
Nov 06, 09:56
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.613M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -91.39% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.3593 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.47% |
Profile
| Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA. |
| URL | http://skyebioscience.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 17, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA. |
| URL | http://skyebioscience.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Growth |
| Next Earnings Release | Nov. 09, 2026 (est.) |
| Last Earnings Release | Aug. 17, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |